|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cyto Pulse Sciences, Inc., the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Volunteers
2/22/2010 11:01:57 AM
GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI). The vaccine will be delivered to healthy volunteers by ZetaJet®, a needle-free injection system (Bioject Medical Technologies Inc.) in combination with the intradermal electroporation system, Derma Vax™ (Cyto Pulse). The study will be sponsored by SMI and conducted at Södersjukhuset, KI, by Principal Investigator Bo Hejdeman, M.D., Ph.D. The multivalent HIV vaccine was developed jointly by SMI and KI.
|
|
|
|
|
|
|
|
|
|
|